Kura Oncology (KURA) Q2 2026 earnings review
KOMZIFTI Launch Accelerates, Validating the Best-in-Class Narrative
Kura Oncology's second full quarter of commercialization for KOMZIFTI (ziftomenib) is a clear success. Product revenue surged 57% sequentially to $9.1 million, driven by 115 new patient starts (up 35%) and over 250 total prescriptions. Management claims they have now captured the majority share of new patient starts in the relapsed/refractory NPM1-m AML menin inhibitor class, effectively overtaking the first-to-market competitor. While the commercial execution is flawless so far, the company is still burning ~$60-70 million per quarter to fund its massive Phase 3 frontline trials, meaning the $519 million cash pile must be carefully managed until the crucial 2028 readouts.
🐂 Bull Case
Taking 'majority share' of new patient starts in the second full quarter post-launch is a massive win. It proves physicians prefer KOMZIFTI's clinical profile (no QTc black box warning) over the incumbent.
Long-term data from KOMET-007 (96% CRc with 7+3 chemo) strongly supports the ongoing KOMET-017 Phase 3 program, which opens the door to a $7 billion total addressable market.
🐻 Bear Case
Net loss was $68.3 million this quarter. While cash sits at $519 million, the pivotal topline results from KOMET-017 aren't due until 2028, requiring flawless execution over a long timeline without dilution.
Despite the 'simpler' safety narrative, the label shows a 26% incidence of Differentiation Syndrome and a 54% dose interruption rate due to adverse reactions. This complicates real-world use.
⚖️ Verdict: 🟢
Bullish. It is rare for a smaller biotech to out-execute an established competitor so cleanly at launch. If KOMZIFTI can maintain this trajectory, Kura's path to becoming the backbone therapy in AML looks highly probable.
Key Themes
Accelerating Commercial Adoption of KOMZIFTI
KOMZIFTI is experiencing rapid, accelerating uptake. Q2 delivered $9.1M in revenue (+57% QoQ), ~115 new patient starts (+35% QoQ), and >250 total prescriptions (+59% QoQ). Achieving a majority share of new patient starts against a first-to-market competitor indicates that Kura's messaging around superior safety and convenient once-daily dosing is resonating strongly with prescribers.
Frontline AML Pipeline: KOMET-017
The true value of ziftomenib lies in the frontline setting. Updated KOMET-007 data at EHA 2026 showed a 96% composite complete remission (CRc) rate and 94% 12-month overall survival when combined with 7+3 intensive chemotherapy. This high and durable clinical activity severely de-risks the ongoing KOMET-017 registrational program, which targets a significantly larger patient pool.
Darlifarnib Showing Efficacy in Solid Tumors
Kura is proving it is not a one-trick pony. The farnesyl transferase inhibitor darlifarnib is yielding compelling data across multiple solid tumors. The FIT-001 trial showed an ORR of 67% in pancreatic cancer and 50% in NSCLC when combined with adagrasib. In cabozantinib-exposed RCC, it drove a 44% ORR and a 94% disease control rate, highlighting its potential to overcome targeted therapy resistance.
Dose Interruption Rates Contradict 'Simple' Narrative
While Kura markets KOMZIFTI as a simpler, safer alternative to competitors, the FDA label data shows that dosage interruption due to an adverse reaction occurred in 54% of patients. Furthermore, permanent discontinuation occurred in 21% of patients. This high rate of interruptions highlights that despite lacking a QTc black box, managing menin inhibitors remains highly complex for clinicians.
Heavy Cash Burn Against a Distant 2028 Catalyst
Cash, equivalents, and short-term investments dropped from $667.2M at the end of 2025 to $519.0M at the end of 26Q2. The company is burning roughly $60M-$70M a quarter. While they anticipate $180M in collaboration payments from Kyowa Kirin to bridge the gap to 2028 Phase 3 readouts, any operational delays could necessitate dilutive funding in the intermediate term.
Reliance on Off-Label Combinations
Management previously noted that ~40% of early KOMZIFTI use was physician-initiated off-label combination therapy (e.g., with venetoclax or FLT3 inhibitors). While this validates the combinability thesis, it creates a revenue base that the company cannot actively promote, making growth harder to forecast until formal label expansions are approved.
Targeting the Broader $7 Billion AML TAM
From a macro perspective, the AML treatment landscape is rapidly shifting toward precision, targeted therapies. Kura's aggressive expansion to evaluate ziftomenib across the entire continuum of care (frontline, intensive, non-intensive, maintenance) aims to capture leadership in a market they estimate at $7 billion, drastically larger than the initial $350-$400 million R/R NPM1-m TAM.
Other KPIs
Stable YoY (compared to $62.8M in 25Q2). The company has successfully scaled its massive global Phase 3 KOMET-017 program and solid tumor trials without causing a massive sequential spike in R&D costs, demonstrating solid operational cost control.
Accelerating. Up from $25.2M in 25Q2, directly reflecting the ongoing commercial buildout and aggressive sales/marketing activities supporting the KOMZIFTI launch.
Guidance
Stable. The company expects its $519.0M current cash plus $180M in anticipated collaboration payments to fund the ziftomenib AML program through the topline results of the first pivotal Phase 3 KOMET-017 trial in 2028.
Stable. Kura expects this non-dilutive capital from its Kyowa Kirin partnership to flow in over the coming periods, which is critical to minimizing dilution.
Key Questions
Combination vs. Monotherapy Breakdown
Of the 115 new patient starts this quarter, what percentage is being driven by off-label combination regimens versus strictly monotherapy use per the label?
Real-World Dose Interruptions
Given the 54% dose interruption rate observed in trials, how are community oncologists managing Differentiation Syndrome in the real world, and is this impacting the duration of therapy?
Frontline Enrollment Pacing
With KOMET-017 enrolling, are you seeing any capacity constraints at clinical sites given the simultaneous expansion of competing frontline menin inhibitor trials by peers like J&J?
Gross-to-Net Trajectory
As payer coverage expands and step-edits potentially take hold, what are the expectations for gross-to-net adjustments for KOMZIFTI through the end of 2026?